, respectively. Procedural success was 99%. Coronary dissections occurred in 14.7%, and bailout BMS was required in 13 patients (11.9%). Mean follow-up was 7.5 months; follow-up rate was 99%. Cumulative MACE at follow-up was 8.7%, with 1% all-cause death, 1% myocardial infarction, 6.9% overall target vessel revascularization; of which 2.9% were target lesion revascularizations, and no vessel thrombosis. Angiographic follow-up of a subset of patients (nϭ26) demonstrated late luminal loss of 0.30 Ϯ 0.36 mm and 0.33 Ϯ 0.37 mm for the in-DCB and in-segment analyses, respectively.
TCT-589
Reaching Further in the Treatment of Calcified Small Vessel Disease -is Rota-DEB an Option? Orta, Almada, Portugal, 3 Hospital de Santa Cruz, CHLO, Carnaxide, Portugal Background: In spite of all the technical developments that have taken place in coronary artery disease treatment, small diffusely calcified vessels are yet challenging. Rotational atherectomy (ROTA) has an undisputed role in the debulking of severely calcified arteries, followed by drug eluting stent implantation for best long term Results. There are cases, however, where delivering a stent proves to be impossible or inappropriate. In such patients (pts) drug eluting balloons (DEB) could provide a therapeutic option. AIMS: We present the preliminary Results of the experience of 3 cardiovascular intervention centers on the use of ROTA followed by DEB (ROTA-DEB). Methods: All data on pts submitted to rotablation is prospectively collected in a database. Pts in which ROTA-DEB was performed, accepted to angiographic follow-up (Fupangio) after a minimum of 6 months. Lesions were assessed by QCA at the time of intervention. Post ROTA-DEB and at Fup, QCA was done after intra coronary administration of nitrates in the same plane as basal QCA and along the length of the DEB. Results: In our multicenter registry, from 1/6/2009 to 31/5/2012, 204 consecutive pts were submitted to ROTA, of which 21 (10.3%) were followed by DEB (32 balloons (average size: 2.45 (2-4) mm x 21.66 (15-30) mm). Most common indications for DEB were: distal vessel Յ 2 mm (59.4%) and difficulties in stent delivering (25%). Angiographic success was achieved in all but 2 lesions(91%): 1 final QCA Ͼ 50% and 1 required bail-out stenting. All pts showed a marked improvement in clinical status. At 12 months, freedom from major cardiac adverse events was 90%. Fup-angio(refused by 3 pts)was obtained at a median of 424 Ϯ 254 days. QCA analysis showed an average late luminal loss (LLL) of -6% (-62% to ϩ75%). LLL Ͼ 50% was present in 1 pt. Conclusions: Although these are still small numbers, Results seem very promising, considering the complexity of the lesions. For very severe, diffusely calcified coronary artery disease, ROTA-DEB constitutes a good therapeutic option when a stent cannot be implanted.
TCT-590
Efficacy Background: The efficacy of paclitaxel-eluting balloon (PEB) for in-stent restenotic lesions is proven; however, its efficacy for recurrences after drug-eluting stent (DES) implantation for in-stent restenosis (stent in stent lesions) remains unclear. The aim of this study was to investigate the efficacy of PEB in patients with recurrences after DES implantation for in-stent restenosis. Background: In comparison to the original PACCOCATH formulation, second generation PCB have improved coating uniformity and decreased drug content variability by modifying coating Methods and processes. In this study, we intended to evaluate the differences in biological efficacy and vascular healing response of 2nd generation PCB in comparison to a 1st generation balloons technologies containing identical coating formulation and drug concentration. Methods: A total of 18 Ilio-femoral arterial segments of 8 FHS were included in the study. At baseline overstretch balloon injury followed by self-expanding BMS implantation was performed. Two weeks following initial injury, all stents were randomized to either a 2nd gen. PCB (nϭ6, Cotavance V2, Medrad), 1st gen. PCB (nϭ6, PACCO-CATH, Medrad) or POBA (nϭ6, control group). Imaging evaluation (QVA, IVUS) was conducted in all animals at baseline, treatment time (2 weeks) and 28 days following treatment. At termination, stented segments were harvested for histopathological evaluation. Results: At last follow up angiographic %DS was significantly reduced in both generations of PCBs when compared to controls (2nd Gen PCB: 11.5Ϯ11.1% vs. 1st Gen PCB: 21.9Ϯ11.0% vs. POBA: 46.5Ϯ10.9%; pϽ0.01). These findings were confirmed by histopathological analysis (see table) displaying an ϳ35% reduction of %AS and neointimal thickness in both PCB groups. Vessel healing defined as fibrin deposition, neointimal maturity and medial cell loss scores was significantly improved in 2nd Gen PCB when compared to 1st Gen PCB. Endothelialization was completed in all three groups. 
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